Перейти к содержанию

Idexx Laboratories Inc (IDXX) stock: revenue, earnings & dividend

Idexx Laboratories Inc (IDXX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener IDXX · Nasdaq Pharma & Biotech US-ME

Key figures

Fiscal year
2025
Revenue
4.3 bn $
Revenue growth
10.4 %
Revenue growth 5y (p.a.)
9.7 %
Net income
1.06 bn $
Net margin
24.6 %
Operating margin
31.6 %
Earnings per share (diluted)
13.08 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
3.35 bn $
Equity
1.61 bn $
Equity ratio
47.9 %
Return on equity
66 %
Cash
180 m $
Operating cash flow
1.18 bn $
Free cash flow
1.06 bn $
Shares outstanding
78,786,265

History

Revenue by fiscal year

2016 1.78 bn $
2017 1.97 bn $
2018 2.21 bn $
2019 2.41 bn $
2020 2.71 bn $
2021 3.22 bn $
2022 3.37 bn $
2023 3.66 bn $
2024 3.9 bn $
2025 4.3 bn $

Net income by fiscal year

2016 222 m $
2017 263 m $
2018 377 m $
2019 428 m $
2020 582 m $
2021 745 m $
2022 679 m $
2023 845 m $
2024 888 m $
2025 1.06 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20254.3 bn $1.06 bn $13.08 $–1.18 bn $
20243.9 bn $888 m $10.67 $–929 m $
20233.66 bn $845 m $10.06 $–907 m $
20223.37 bn $679 m $8.03 $–543 m $
20213.22 bn $745 m $8.60 $–756 m $
20202.71 bn $582 m $6.71 $–648 m $
20192.41 bn $428 m $4.89 $–459 m $
20182.21 bn $377 m $4.26 $–400 m $
20171.97 bn $263 m $2.94 $–373 m $
20161.78 bn $222 m $2.44 $––

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)